Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost €15.00 Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost quantity Add to cart Category: Articles Tag: Volume 3 Description Description Authors: Janet B. Serle, Jake Radell Related products Molecular differences in segmental regions of the trabecular meshwork €15.00 Add to cart IOP homeostasis ? Why most people do not ever develop glaucoma €15.00 Add to cart The role of blood flow in glaucoma €15.00 Add to cart Novel surgical methods for addressing glaucoma €15.00 Add to cart